AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study

被引：0
|
作者：
Cortes, Jorge [1 ]
Foran, James [8 ]
Ghirdaladze, Darejan [7 ]
DeVetten, Marcel P. [6 ]
Zodelava, Mamia [5 ]
Holman, Peter [4 ]
Levis, Mark J. [3 ]
Kantarjian, Hagop M. [1 ]
Borthakur, Gautam [1 ]
James, Joyce [2 ]
Zarringkar, Patrick P. [2 ]
Gunawardane, Ruwanthi N. [2 ]
Armstrong, Robert C. [2 ]
Padre, Norman M. [2 ]
Wierenga, Wendell [2 ]
Corringham, Robert [2 ]
Trikha, Mohit [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Ambit Biosci, San Diego, CA USA
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] Univ Calif San Diego, La Jolla, CA 92093 USA
[5] Hema Clin, Tbilisi, Georgia
[6] Univ Nebraska, Med Ctr, Omaha, NE USA
[7] Medulla Clin, Tbilisi, Georgia
[8] Univ Alabama Birmingham, Birmingham, AL USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：264 / 264
页数：1
相关论文
共 50 条
  • [31] Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
    Perl, Alexander E.
    Altman, Jessica K.
    Cortes, Jorge
    Smith, Catherine
    Litzow, Mark
    Baer, Maria R.
    Claxton, David
    Erba, Harry P.
    Gill, Stan
    Goldberg, Stuart
    Jurcic, Joseph G.
    Larson, Richard A.
    Liu, Chaofeng
    Ritchie, Ellen
    Schiller, Gary
    Spira, Alexander I.
    Strickland, Stephen A.
    Tibes, Raoul
    Ustun, Celalettin
    Wang, Eunice S.
    Stuart, Robert
    Roellig, Christoph
    Neubauer, Andreas
    Martinelli, Giovanni
    Bahceci, Erkut
    Levis, Mark
    LANCET ONCOLOGY, 2017, 18 (08): : 1061 - 1075
  • [32] First-in-human (FIH) phase I study of GST-HG161, a potent and highly selective c-met inhibitor, in patients with advanced solid tumor.
    Li, Jin
    Guo, Ye
    Xue, Junli
    Wu, Wenqiang
    Chen, Shikui
    Tang, Yanan
    Xu, Xiongbin
    Li, Gang
    Hu, Lihong
    Lin, Yunfei
    Shen, Liang
    Xia, Yuanfeng
    Chan, Chi-Chung
    Wang, Zhouchong
    Ni, Dawen
    Ding, Charles
    Chen, Shuhui
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] CHIR258: A multitargeted growth factor receptor tyrosine kinase (RTK) inhibitor induces significant apoptosis of human FLT3 ITD acute myelogenous leukemia cells in vitro and in vivo
    Menezes, DL
    Wiesmann, M
    Lee, SH
    Lee, I
    Peng, J
    Tang, Y
    Ye, H
    Oei, Y
    Goldbeck, C
    Garrett, EN
    Heise, C
    BLOOD, 2004, 104 (11) : 496A - 496A
  • [34] An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia
    Sanga, Madhu
    James, Joyce
    Marini, Joseph
    Gammon, Guy
    Hale, Christine
    Li, Jianke
    XENOBIOTICA, 2017, 47 (10) : 856 - 869
  • [35] A first-in-human (FIH) phase I study of SAR12544, a novel selective MET kinase inhibitor, in patients (pts) with advanced solid tumors: Dose escalation results
    Angevin, Eric
    Spitaleri, Gianluca
    Hollebecque, Antoine
    De Pas, Tommaso
    Soria, Jean-Charles
    Harnols, Marzia
    Mazuir, Florent
    Assadourlan, Sylvie
    De Marinis, Filippo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia
    Yoon, Sung-Soo
    Shin, Dong-Yeop
    Lee, Je-Hwan
    Jang, Jun Ho
    Cheong, June-Won
    Shin, Ho-Jin
    Lee, Jeong-Ok
    Choi, Yunsuk
    Puliyayil, Anish
    Clarey, Joseph
    Jeejinlm
    Nam, Ly-Youb
    Kim, Kyu-Tae
    Han, June H-J.
    Yoon, Jeong-Hyeok
    Nguyen, Bao
    Li, Li
    Small, Donald
    BLOOD, 2021, 138
  • [37] A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification
    Angevin, Eric
    Spitaleri, Gianluca
    Rodon, Jordi
    Dotti, Katia
    Isambert, Nicolas
    Salvagni, Stefania
    Moreno, Victor
    Assadourian, Sylvie
    Gomez, Corinne
    Harnois, Marzia
    Hollebecque, Antoine
    Azaro, Analia
    Hervieu, Alice
    Rihawi, Karim
    De Marinis, Filippo
    EUROPEAN JOURNAL OF CANCER, 2017, 87 : 131 - 139
  • [38] First-in-human Safety, Pharmacokinetics and Pharmacodynamics of THB001: An Orally Available, Potent and Highly Selective Small Molecule Inhibitor of Wild Type KIT Receptor Tyrosine Kinase
    Sweeney, Steven
    Voors-Pette, Christine
    Nijhuis, Jerome Oude
    Keaney, Gregg
    Parry, Graham
    Conner, Edward
    Nix, Darrell
    Rioux, Nathalie
    DiRico, Amy
    Yoo, Stephen
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB51 - AB51
  • [39] First-in-human study of simmitinib, a novel tyrosine kinase inhibitor targeting FGFR1-3, KDR and CSF-1R
    Yang, Sheng
    Zhang, Yanqiao
    Zhang, Mingjun
    Wu, Yongzhong
    Li, Yongsheng
    Wang, Feng
    Tian, Xin
    Luo, Suxia
    Sun, Yuping
    Wang, Linlin
    Li, Jiancheng
    Jiang, Da
    Wang, Mingxia
    Huang, Yunchao
    Shi, Huaqiu
    Yang, Haiyu
    Liu, Xiaowen
    Ji, Wei
    Pu, Weiqing
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs).
    Schoffski, Patrick
    Heinrich, Michael C.
    Trent, Jonathan C.
    Serrano, Cesar
    Bauer, Sebastian
    von Mehren, Margaret
    Somaiah, Neeta
    Reichardt, Peter
    Demetri, George D.
    Lydon, Nick
    Verweij, Jaap
    Kadambi, Vivek
    Christo, Jessica
    Kim, Sean
    Johnson, Debbie
    Shao, James
    George, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345